^
Association details:
| Biomarker: | BCR-ABL1 fusion + SET underexpression |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
THE STUDY OF SET GENE AND PROTEIN PHOSPHATASE 2A IN CHRONIC MYELOID LEUKEMIA AND THEIR ROLE IN DISEASE PROGRESSION
Published date:
05/12/2022
Excerpt:
The study included 50 CML patients under TKI therapy for at least 18 months, and 50 healthy controls....High SET gene expression in patients was found to be significantly associated with advanced disease phase and worse clinical and laboratory findings while low expression was significantly associated with better molecular response assessed by BCR-ABL1 level.
